Sign In
Buy IONS
$75.99
+0.1000 (+0.132%)
At Close: Jun 23, 2026
Ionis Pharmaceuticals, Inc. (IONS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
01:22pm, Wednesday, 10'th Jun 2026
Ionis Pharmaceuticals, Inc. (IONS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
08:00am, Monday, 08'th Jun 2026
[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) today announced the appointment of Ludwig Hantson, Ph.D., an accomplished global biopharmaceutical leade
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
07:00am, Monday, 08'th Jun 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Ludwig Hantson, Ph.D., an accomplished global biopharmaceutical leader, to the Ionis Bo
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
01:05pm, Friday, 05'th Jun 2026
Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.
Ionis Pharmaceuticals, Inc. (IONS) Discusses Progress in RNA Therapeutics and Transition to Commercial-Stage Biotechnology Transcript
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data analyses from the landmark Phase 3 CORE and CORE2 studies of olezarsen in people with severe
Why Is Ionis Pharmaceuticals (IONS) Up 3.4% Since Last Earnings Report?
12:32pm, Friday, 29'th May 2026
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Ionis Pharmaceuticals: Bull Run Can Continue As Major Catalysts Approach
03:32pm, Thursday, 28'th May 2026
Ionis Pharmaceuticals remains a Buy, with a compelling bull case despite a >125% 12-month share price increase. IONS is transitioning from niche indications to multi-billion-dollar markets, leveraging
[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligon
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligonucleotide (ASO) for
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts
08:07pm, Monday, 25'th May 2026
Ionis Pharmaceuticals NASDAQ: IONS highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets' Global Healthcare Conference
Ionis Pharmaceuticals, Inc. (IONS) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
10:10am, Tuesday, 19'th May 2026
Ionis Pharmaceuticals, Inc. (IONS) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference
06:05am, Monday, 18'th May 2026
Executives at a healthcare investor event outlined commercial launch plans, pipeline readouts and market-development priorities across several biotechnology franchises, with discussion spanning Ionis
BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal
12:31pm, Friday, 15'th May 2026
Biogen advances Alzheimer's drug diranersen to late-stage trials after a phase II study misses its main goal but shows cognitive and biomarker gains.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared compelling topline results from the Phase 2 CELIA study evaluating dirane
